TriSalus Life Sciences, Inc. TLSI Derivative, Gain (Loss) on Derivative, Net
Derivative, Gain (Loss) on Derivative, Net at other companies
Other financials
Where this comes from
Reported directly by TriSalus Life Sciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:DerivativeGainLossOnDerivativeNet.
The official record: TriSalus Life Sciences, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net?
- TriSalus Life Sciences, Inc. (TLSI) reported derivative, gain (loss) on derivative, net of $3.9M in Q1 2026.
- How has TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net changed year-over-year?
- TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net increased by 567.1% year-over-year, from -$835K to $3.9M.
- What is the long-term trend for TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net?
- Over 2 years (2022 to 2025), TriSalus Life Sciences, Inc.'s derivative, gain (loss) on derivative, net has grown at a 36.9% compound annual growth rate (CAGR), from -$2.19M to -$4.1M.